Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of osmotic laxative (PEG-3350, sodium chloride, sodium bicarbonate, potassium chloride) and stimulant laxative (bisacodyl). PEG-3350 causes water retention in colon, increasing stool water content and volume, stimulating peristalsis. Electrolytes maintain fluid/electrolyte balance. Bisacodyl stimulates colonic smooth muscle contraction and inhibits water absorption.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients,Colonoscopy preparation in patients with renal impairment or electrolyte abnormalities (off-label)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
For colonoscopy preparation: Day 1: 4 bisacodyl tablets (5 mg each) orally at 2000. Day 2: 1 liter of PEG-3350 plus electrolytes solution (4 sachets dissolved in 4 liters water) orally at 0800; then 2 liters more over 3-4 hours. Alternatively, split-dose regimen: 2 liters evening before colonoscopy and 2 liters morning of procedure.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
PEG-3350: not applicable (non-absorbed). Bisacodyl: terminal half-life 8–16 hours; clinical effect peaks within 6–12 hours.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
PEG-3350 is not metabolized; excreted unchanged in feces. Bisacodyl is metabolized in the liver and small intestine to its active metabolite, bis-(p-hydroxyphenyl)-pyridyl-2-methane, by ester hydrolysis. Electrolytes are absorbed or secreted by normal physiological mechanisms.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
PEG-3350 is not absorbed, excreted unchanged in feces. Electrolytes (sodium chloride, sodium bicarbonate, potassium chloride) are absorbed and renally excreted; bisacodyl is primarily excreted as glucuronide conjugates in feces (biliary) and urine (renal). Approximately 95% of bisacodyl is recovered in feces, 5% in urine.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
PEG-3350: negligible (non-absorbed). Bisacodyl: ~90% bound to plasma proteins.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
PEG-3350: not distributed (non-absorbed). Bisacodyl: Vd approximately 0.4–0.6 L/kg, indicating moderate tissue distribution.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
PEG-3350: negligible systemic absorption (<0.2%). Bisacodyl: oral bioavailability 15–30% due to first-pass metabolism; rectal bioavailability ~50%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to risk of electrolyte disturbances. In moderate impairment (Cr Cl 30-50 m L/min): use with caution, monitor electrolytes. No dose adjustment specified by manufacturer for mild impairment.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific dose adjustment required for hepatic impairment based on Child-Pugh class. However, use with caution in severe hepatic impairment due to potential for encephalopathy from electrolyte shifts.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Not FDA-approved for children <2 years. For children 2-11 years: PEG-3350 plus electrolytes 75-100 m L/kg/dose orally, up to 4 L, for colonoscopy preparation. Bisacodyl tablets: children 6-11 years: 2.5-5 mg orally at bedtime day before procedure. Weight-based: not standardized; refer to specific pediatric protocols.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Use with caution due to increased risk of electrolyte imbalance and dehydration. No specific dose reduction recommended; however, consider lower volume (2 L) split-dose regimen. Monitor renal function and electrolytes before and after procedure.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
WARNING: SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES. There have been reports of significant fluid shifts, severe electrolyte abnormalities (including hypokalemia, hyponatremia), and dehydration in patients treated with this product. The risk is increased in patients with renal insufficiency, electrolyte abnormalities, or those taking concomitant medications that affect electrolytes. Monitor and correct fluid and electrolyte disturbances before use.
None.
Risk of electrolyte abnormalities and dehydration; correct before use,Use with caution in patients with renal impairment, electrolyte disturbances, or taking diuretics, ACE inhibitors, or NSAIDs,Risk of serious arrhythmias due to electrolyte imbalance,Possible colonic mucosal ulcerations (aphthoid ulcers) with bisacodyl,Gag reflex may be impaired in elderly, debilitated, or patients with swallowing disorders; risk of aspiration,May cause Mallory-Weiss tear or esophageal perforation if vomiting occurs,Monitor for QT prolongation in at-risk patients
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Known hypersensitivity to any component,Gastrointestinal obstruction, ileus, gastric retention, bowel perforation, toxic colitis, toxic megacolon,Significant electrolyte abnormalities (e.g., severe hypokalemia, hyponatremia),Renal impairment (e.g., creatinine clearance < 30 m L/min) for formulations with high PEG-3350 content (note: this product contains lower PEG dose, but caution still warranted),Pregnancy (relative contraindication; use only if clearly needed),Patients with impaired consciousness
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid solid foods, dairy, and red/purple colored liquids during preparation. Only clear liquids (water, clear broth, apple juice, gelatin, tea or coffee without cream) are permitted until after the procedure.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
First trimester: Minimal systemic absorption; no known teratogenic effects. Second/third trimester: Avoid use due to risk of electrolyte imbalance and fluid shifts; not associated with congenital anomalies.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Bisacodyl and polyethylene glycol are not excreted in breast milk in significant amounts; M/P ratio unknown. Minimal systemic absorption suggests low risk. Use with caution due to potential gastrointestinal effects in infant.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No standard dose adjustments established; avoid use in pregnancy due to lack of safety data. If used, standard dosing for bowel preparation should be individualized with close monitoring.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
This combination is used for colonoscopy preparation. Ensure adequate hydration and renal function assessment; avoid in patients with ileus, GI obstruction, or significant electrolyte abnormalities. Bisacodyl is a stimulant laxative that may cause cramping. Administer in divided doses as per protocol.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Drink plenty of clear liquids to stay hydrated.,Follow the exact dosing schedule provided by your doctor.,Expect frequent, watery bowel movements; stay near a restroom.,Do not eat solid foods during the preparation; only clear liquids.,Notify your doctor if you experience severe abdominal pain, vomiting, or signs of dehydration.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Mycophenolic acid, a prodrug of mycophenolate mofetil, undergoes enterohepatic recirculation and is absorbed in the stomach and proximal small intestine. Sodium bicarbonate, by raising gastric pH, can reduce the dissolution and absorption of mycophenolic acid, leading to decreased systemic exposure and potentially reduced immunosuppressive efficacy. This interaction may increase the risk of transplant rejection when used concurrently."
"Sodium bicarbonate, an alkalizing agent, can increase the gastric pH, which may reduce the dissolution and absorption of topically administered clobetasol propionate if swallowed inadvertently. However, this interaction is not clinically significant for topical application, as systemic absorption of clobetasol is minimal. The theoretical decrease in bioavailability is unlikely to affect efficacy or safety."
"Perphenazine, a phenothiazine antipsychotic, can reduce the absorption of sodium bicarbonate by delaying gastric emptying and increasing gastrointestinal transit time. This results in decreased systemic availability of bicarbonate, potentially attenuating its alkalinizing effect and compromising its efficacy in conditions requiring urinary alkalinization or systemic acidosis correction."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL is a Electrolyte that works by Combination of osmotic laxative (PEG-3350, sodium chloride, sodium bicarbonate, potassium chloride) and stimulant laxative (bisacodyl). PEG-3350 causes water retention in colon, increasing stool water content and volume, stimulating peristalsis. Electrolytes maintain fluid/electrolyte balance. Bisacodyl stimulates colonic smooth muscle contraction and inhibits water absorption.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL is: For colonoscopy preparation: Day 1: 4 bisacodyl tablets (5 mg each) orally at 2000. Day 2: 1 liter of PEG-3350 plus electrolytes solution (4 sachets dissolved in 4 liters water) orally at 0800; then 2 liters more over 3-4 hours. Alternatively, split-dose regimen: 2 liters evening before colonoscopy and 2 liters morning of procedure.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL is classified as Category A/B. First trimester: Minimal systemic absorption; no known teratogenic effects. Second/third trimester: Avoid use due to risk of electrolyte imbalance and fluid shifts; not associated . ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.